MedTrace Logo

Telaglenastat + Talazoparib In Prostate Cancer

NCT04824937 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-01

No results posted yet for this study

Summary

The purpose of this research is to test the effectiveness of an experimental drug combination for people with metastatic castration-resistant prostate cancer (mCRPC).

The names of the study drugs involved in this study are:

* Telaglenastat (CB-839)
* Talazoparib

Conditions

  • Prostate Cancer Metastatic

Interventions

DRUG

Telaglenastat

Capsule, taken by mouth

DRUG

Talazoparib

Capsule, taken by mouth

Sponsors & Collaborators

  • Calithera Biosciences, Inc

    collaborator INDUSTRY

  • Pfizer

    collaborator INDUSTRY

  • Prostate Cancer Foundation

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Richard J Lee, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-31
Primary Completion
2021-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04824937 on ClinicalTrials.gov